Expression of costimulatory molecules on human retinoblastoma cells Y-79: Functional expression of CD40 and B7H1

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4607-4613

  Usui, Yoshihiko ^a   Okunuki, Youko ^a   Hattori, Takaaki ^a   Takeuchi, Masaru ^a   Kezuka, Takeshi ^a   Goto, Hiroshi ^a   Usui, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 IBBL ANTIGEN; ANTIGEN; B7 ANTIGEN; B7DC ANTIGEN; B7H1 ANTIGEN; B7H2 ANTIGEN; CD134 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; LEUKOCYTE ANTIGEN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT GAMMA INTERFERON;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNITY; CELL CULTURE; COCULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; RADIATION EXPOSURE; RETINA TUMOR; UPREGULATION;

ANTIGENS, CD; ANTIGENS, CD40; CHEMOKINE CCL2; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA, RECOMBINANT; LYMPHOCYTE ACTIVATION; RETINAL NEOPLASMS; RETINOBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33750601231     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0181     Document Type: Article

References (47)

1. Ferris FL. 3rd, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.
2. O'Brien JM. Alternative treatment in retinoblasloma. Ophthalmology. 1998;105:571-572.
3. Chantada G, Fandino A, Davila MT. et al. Results of a prospective study for the treatment of retinoblastoma. Cancer. 2004;100:834-842.
4. Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004;24:849-862.
5. Blank C, Gajewski TF, Mackensen A. Interaction of PD-LI on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307-314.
6. Madigan MC, Penfold PL. Human retinoblastoma: a morphological study of apoptolic, leukocytic, and vascular elements. Ultrastruct Pathol. 1997;21:95-107.
7. Barez S, Boumpas DT, Percopo CM, Anastassiou ED, Hooks JJ, Detrick B. Modulation of major histocompatibilily complex class 1 genes in human retinoblastoma cells by interferons. Invest Ophthalmol Vis Sci. 1993;34:2613-2621.
8. Madigan MC, Penfold PL, King NJ, Billson FA, Conway RM. Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines. Oncol Res. 2002;13:103-111.
9. Conway RM, Madigan MC, King NJ, Billson FA, Penfold PL. Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid. Cancer Immunol Immunother. 1997;44:189-196.
10. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
11. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol. 2001;22:217-223.
12. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol. 1992;10:617-644.
13. Pirozzi G, Lombari V, Zanzi D, et al. CD-40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. Int Immunol. 2000;12:787-795.
14. von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999;59:1287-1294.
15. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD 137) ligand on carcinoma cells. J Immunol. 2000;165:2903-2910.
16. Schreiner B, Wischhusen J, Mitsdoerffer M, et al. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia. 2003;44:296-301.
17. Guinan EC, Gribben JG, Bonssiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994;84:3261-3282.
18. Chambers CA. Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594.
19. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462-7467.
20. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337-365.
21. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol. 2000;12:589-596.
22. Wu TC, Huang AY, Jaffee EM, Levitsky Hl, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995;182:1415-1421.
23. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164:2160-2169.
24. Liu X, Bai XF, Wen J, et al. B7H costimulates clonal expansion of and cognate destruction of tumor cells by, CD8(+) T lymphocytes In vivo. J Exp Med. 2001;194:1339-1348.
25. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
26. Yoshizawa H, Kagamu H, Gejyo F. Cancer immunogene therapy. Arch Immunol Ther Exp (Warsz). 2001;49:337-343.
27. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocytc-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
28. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des. 2002;8:1765-1780.
29. Reid TW, Albert DM, Rabson AS, et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst. 1974;53:347-360.
30. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today. 1996;17:487-492.
31. Grewal IS, Flavell RA. CD40 and CD 154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
32. Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000;37:515-526.
33. Altenhurg A, Baldus SE, Smola H, Pfister H, Hess S. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol. 1999;162:4140-4147.
34. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by 1L-2. Eur J Immunol. 2002;32:634-643.
35. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562-567.
36. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
37. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268.
38. Katsanis E, Xu Z, Bausero MA, et al. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther. 1995;2:39-46.
39. Enomoto A, Kato K, Yagita U, Okumura K. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice. Cancer Immunol Immunother. 1997;44:204-210.
40. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein I acts as a T-Iyniphocyte chemoattractant. Proc Natl Acad Sci USA. 1994;91:3652-3656.
41. Katsanis E, Bausero MA, Xu H, et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases 1CAM-2-dependent killing. Cancer Immunol Immunother. 1994;38:135-141.
42. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995;55:3149-3157.
43. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280-3287.
44. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
45. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cll immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501-6505.
46. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293-12297.
47. Uno T, Chen PW, Murray TG, Podack ER, Ksander BR. Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. Invest Ophtbalmol Vis Sci. 1997;38:2531-2539.